PODD Stock Analysis: Insulet | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 10.578m USD | 12M Return: -60.4% | US45784P1012 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 200M
EPS Trend: 97.7%
Qual. Beats: 3
Rev. Trend: 99.8%
Qual. Beats: 13
Warnings
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Insulet Corporation (NASDAQ: PODD) is a U.S.-based mid-cap health care equipment company that develops, manufactures, and sells insulin delivery systems primarily for people with insulin-dependent diabetes. Its core product family is the Omnipod platform, a line of tubeless, wearable insulin pumps that include the Omnipod 5 automated insulin delivery system (integrated with third-party continuous glucose monitors via Bluetooth), the Omnipod DASH system (smartphone-controlled), and the legacy Omnipod Insulin Management System.
The company also supplies pods to Amgen for use in the Neulasta Onpro kit, a drug delivery system designed to reduce infection risk following intensive chemotherapy. Insulet sells its diabetes products directly to end-users through the pharmacy channel and via independent distributors, with operations spanning the United States and international markets. Insulet was incorporated in 2000 and is headquartered in Acton Massachusetts.
- Omnipod 5 adoption drives U.S. type 2 diabetes expansion
- Tubeless pump competition intensifies versus Medtronic and Tandem
- Gross margins expand as automated manufacturing scales globally
| Net Income: 428.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -6.29 > 1.0 |
| NWC/Revenue: 38.48% < 20% (prev 48.05%; Δ -9.57% < -1%) |
| CFO/TA 0.15 > 3% & CFO 509.0m > Net Income 428.8m |
| Net Debt (382.3m) to EBITDA (718.6m): 0.53 < 3 |
| Current Ratio: 2.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.5m) vs 12m ago -1.65% < -2% |
| Gross Margin: 71.88% > 18% (prev 71.46%; Δ 0.42% > 0.5%) |
| Asset Turnover: 98.98% > 50% (prev 83.25%; Δ 15.73% > 0%) |
| Interest Coverage Ratio: 10.24 > 6 (EBIT TTM 613.1m / Interest Expense TTM 59.9m) |
| A: 0.36 (Total Current Assets 2.04b - Total Current Liabilities 814.4m) / Total Assets 3.42b |
| B: 0.18 (Retained Earnings 614.5m / Total Assets 3.42b) |
| C: 0.19 (EBIT TTM 613.1m / Avg Total Assets 3.22b) |
| D: 0.86 (Book Value of Equity 1.58b / Total Liabilities 1.84b) |
| Altman-Z'' = 5.13 = AAA |
| DSRI: 1.18 (Receivables 689.0m/462.2m, Revenue 3.19b/2.52b) |
| GMI: 0.99 (GM 71.46% / 71.88%) |
| AQI: 0.91 (AQ_t 0.13 / AQ_t-1 0.15) |
| SGI: 1.26 (Revenue 3.19b / 2.52b) |
| TATA: -0.02 (NI 428.8m - CFO 509.0m) / TA 3.42b) |
| Beneish M = -2.75 (Cap -4..+1) = A |
As of November 20, 2026, the stock is trading at USD 137.23 with a total of 1,553,033 shares traded. Over the past week, the price has changed by -8.08%, over one month by -3.33%, over three months by -9.43% and over the past year by -60.38%.
Current recommended Stop Loss: 124.60 (which is 9.2% or 1.9 ATR below the current price).
Insulet has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy PODD.
- StrongBuy: 11
- Buy: 4
- Hold: 11
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 178.6 | 30.1% |
P/E Trailing = 24.915
P/E Forward = 19.7628
P/S = 3.3167
P/B = 6.6986
P/EG = 1.1898
Revenue TTM = 3.19b USD
EBIT TTM = 613.1m USD
EBITDA TTM = 718.6m USD
Long Term Debt = 943.0m USD (from longTermDebt, last quarter)
Short Term Debt = 19.1m USD (from shortTermDebt, last quarter)
Debt = 966.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.60m
Net Debt = 382.3m USD (calculated: Debt 966.7m - CCE 584.4m)
Enterprise Value = 11.0b USD (10.6b + Debt 966.7m - CCE 584.4m)
Interest Coverage Ratio = 10.24 (Ebit TTM 613.1m / Interest Expense TTM 59.9m)
EV/FCF = 42.15x (Enterprise Value 11.0b / FCF TTM 260.0m)
FCF Yield = 2.37% (FCF TTM 260.0m / Enterprise Value 11.0b)
FCF Margin = 8.15% (FCF TTM 260.0m / Revenue TTM 3.19b)
Net Margin = 13.45% (Net Income TTM 428.8m / Revenue TTM 3.19b)
Gross Margin = 71.88% ((Revenue TTM 3.19b - Cost of Revenue TTM 896.8m) / Revenue TTM)
Gross Margin QoQ = 75.07% (prev 70.18%)
Tobins Q-Ratio = 3.21 (Enterprise Value 11.0b / Total Assets 3.42b)
Interest Expense / Debt = 6.20% (Interest Expense 59.9m / Debt 966.7m)
Taxrate = 21.89% (120.2m / 549.1m)
NOPAT = 478.9m (EBIT 613.1m * (1 - 21.89%))
Current Ratio = 2.51 (Total Current Assets 2.04b / Total Current Liabilities 814.4m)
Debt / Equity = 0.61 (Debt 966.7m / totalStockholderEquity, last quarter 1.58b)
Debt / EBITDA = 0.53 (Net Debt 382.3m / EBITDA 718.6m)
Debt / FCF = 1.47 (Net Debt 382.3m / FCF TTM 260.0m)
Total Stockholder Equity = 1.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.31% (Net Income 428.8m / Total Assets 3.42b)
RoE = 29.48% (Net Income TTM 428.8m / Total Stockholder Equity 1.45b)
RoCE = 25.57% (EBIT 613.1m / Capital Employed (Equity 1.45b + L.T.Debt 943.0m))
RoIC = 19.46% (NOPAT 478.9m / Invested Capital 2.46b)
WACC = 6.17% (E(10.6b)/V(11.5b) * Re(6.29%) + D(966.7m)/V(11.5b) * Rd(6.20%) * (1-Tc(0.22)))
Discount Rate = 6.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.26 | Cagr: -2.64%
[DCF] Terminal Value 73.10% ; FCFF base≈324.5m ; Y1≈284.5m ; Y5≈229.9m
[DCF] Fair Price = 47.68 (EV 3.69b - Net Debt 382.3m = Equity 3.31b / Shares 69.4m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 97.71 | EPS CAGR: 34.49% | SUE: 4.0 | # QB: 3
Revenue Correlation: 99.81 | Revenue CAGR: 26.97% | SUE: 1.18 | # QB: 13
EPS current Quarter (2027-03-31): EPS=1.66 | Chg30d=+1.85% | Revisions=+7% | Analysts=18
EPS current Year (2026-12-31): EPS=6.77 | Chg30d=+4.11% | Revisions=+75% | GrowthEPS=+36.3% | GrowthRev=+22.0%
EPS next Year (2027-12-31): EPS=7.91 | Chg30d=+2.37% | Revisions=+32% | GrowthEPS=+16.8% | GrowthRev=+11.7%
[Analyst] Revisions Ratio: +47% (up=33, down=11)